ClinVar Miner

Submissions for variant NM_000179.2(MSH6):c.1109T>C (p.Leu370Ser) (rs587779204)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000162441 SCV000212790 likely pathogenic Hereditary cancer-predisposing syndrome 2018-03-27 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient evidence,Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation,Good segregation with disease (lod 1.5-3 = 5-9 meioses),In silico models in agreement (deleterious) and/or completely conserved position in appropriate species,Rarity in general population databases (dbsnp, esp, 1000 genomes),Other data supporting pathogenic classification,Moderate segregation with disease (at least 3 informative meioses) for rare diseases.
Color RCV000162441 SCV000685164 uncertain significance Hereditary cancer-predisposing syndrome 2018-06-29 criteria provided, single submitter clinical testing
GeneDx RCV000518839 SCV000568050 likely pathogenic not provided 2018-06-11 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.1109T>C at the cDNA level, p.Leu370Ser (L370S) at the protein level, and results in the change of a Leucine to a Serine (TTA>TCA). MSH6 Leu370Ser has been reported in at least two patients with endometrial cancer, one of whose tumor demonstrated absence of MSH6 on immunohistochemistry (Egoavil 2013, Batte 2014). This variant was also identified in an individual with colorectal cancer, whose tumor studies demonstrated mismatch repair deficiency via immunohistochemistry (IHC) and/or microsatellite instability; and the variant also demonstrated extensive co-segregation among the proband and affected family members (Pearlman 2017). MSH6 Leu370Ser was not observed in large population cohorts (Lek 2016). This variant is located in the mismatch binding domain and nuclear localization signal region (Warren 2007, Gassman 2011, Kansikas, 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, we consider MSH6 Leu370Ser to be a likely pathogenic variant.
Invitae RCV000524101 SCV000261301 likely pathogenic Hereditary nonpolyposis colon cancer 2018-12-26 criteria provided, single submitter clinical testing This sequence change replaces leucine with serine at codon 370 of the MSH6 protein (p.Leu370Ser). The leucine residue is moderately conserved and there is a large physicochemical difference between leucine and serine. This variant is not present in population databases (rs587779204, ExAC no frequency). This variant has been observed in several individuals affected with endometrial cancer and/or colorectal cancer (PMID: 24933100, 24244552, Invitae). Moreover, it has been observed to segregate with Lynch syndrome related cancers in one family (PMID: 27978560). ClinVar contains an entry for this variant (Variation ID: 89172). An algorithm developed specifically for the MSH6 gene suggests that this missense change is likely to be deleterious (PMID: 23621914). However, this prediction has not been confirmed by published functional studies and its clinical significance is uncertain. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000202023 SCV000257204 uncertain significance not specified no assertion criteria provided research
University of Washington Department of Laboratory Medicine,University of Washington RCV000074633 SCV000579493 pathogenic Lynch syndrome 2016-05-17 criteria provided, single submitter clinical testing Co-segregation likelihood ratio >250, shared with 3th cousin with loss of MSH6 and others with Lynch cancers in large pedigree, likelihood ration for cosegregation >250

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.